Trump's Healthcare Plan: Policy Analysis and Investment Implications

On January 15, 2026, President Donald J. Trump unveiled “The Great Healthcare Plan,” a comprehensive framework aimed at lowering drug prices, reducing insurance premiums, enhancing price transparency, and restructuring federal healthcare subsidies [1][2]. This plan builds upon executive actions taken throughout 2025, including the “Most-Favored-Nation” drug pricing executive order signed in May 2025, which has already secured voluntary pricing agreements with 16 major pharmaceutical manufacturers [2]. The policy proposals span multiple healthcare subsectors—including pharmaceutical companies, health insurers, pharmacy benefit managers (PBMs), and healthcare service providers—and carry significant implications for investor portfolios.

---

The cornerstone of Trump’s healthcare agenda is the codification of “Most-Favored-Nation” (MFN) drug pricing, which would require pharmaceutical companies to offer American patients the same prices paid in comparable developed nations [1][2]. This policy represents a fundamental shift from the Biden administration’s Inflation Reduction Act (IRA) price negotiation framework, replacing government-mandated negotiations with a market-based international reference pricing system.

The administration has already secured 16 voluntary agreements with major pharmaceutical manufacturers, including AbbVie, which agreed to provide reduced Medicaid prices in exchange for tariff exemptions and a $100 billion US investment commitment over ten years [3]. These voluntary deals will be “grandfathered in” under the new legislative framework, providing companies with regulatory certainty in exchange for pricing concessions.

Company	Response	Investment Impact
AbbVie (ABBV)	Signed voluntary agreement; $100B US investment pledge	Secured pricing stability; tariff protection
Eli Lilly (LLY)	Engaged in negotiations; expanding US manufacturing	Potential MFN pricing; domestic production costs
Novo Nordisk (NVO)	Facing GLP-1 pricing pressure; FDA facility issues	Margin compression on weight-loss drugs
Merck (MRK)	Evaluating deal structure	Exposure to oncology drug pricing

The pharmaceutical sector faces a complex calculus: reduced US pricing margins balanced against tariff exemptions and market access guarantees. Companies with significant international revenue exposure may experience compression of their US drug pricing while maintaining or even increasing prices in international markets—a strategy that could sustain overall profitability [4]. BDO International’s 2026 Life Sciences predictions suggest that pharmaceutical companies will prioritize domestic manufacturing investments to mitigate tariff risks, despite the multi-year timeline required to establish production facilities [4].

• R&D Investment Pressure
  : Reduced pricing may constrain research budgets, potentially favoring companies with diversified revenue streams and robust pipelines
• Manufacturing Reshoring
  : Companies announcing US manufacturing investments (e.g., AbbVie’s $100 billion commitment) may receive preferential treatment in tariff negotiations
• Generic/Biosimilar Acceleration
  : Price compression on branded drugs could accelerate adoption of lower-cost alternatives, impacting innovation-focused pharmaceutical companies

---

The Great Healthcare Plan proposes a fundamental restructuring of how federal healthcare subsidies are distributed, shifting from direct payments to insurance companies toward direct consumer subsidies [1][2]. Key components include:

1. Termination of Taxpayer-Funded Subsidy Payments to Large Insurance Companies
   : Redirecting funds to individual Americans for insurance purchases
2. Cost-Sharing Reduction Program
   : Projected to save taxpayers at least $36 billion and reduce ACA plan premiums by over 10% according to Congressional Budget Office estimates [2]
3. Enhanced Price Transparency
   : Mandatory disclosure of claims payout ratios, overhead/profits percentages, and claim rejection rates

Major health insurers face significant operational and financial uncertainty under the proposed restructuring:

• UnitedHealth Group (UNH) stock declined 34-35% in 2025, underperforming the S&P 500’s 16% gain [5][6]
• The decline was attributed to CEO transition, Medicare billing investigations, and elevated medical loss ratios
• Despite challenges, the stock has shown signs of recovery as investors reassess valuation opportunities [5]

Company	Ticker	Current Positioning	Policy Risk Level
UnitedHealth Group	UNH	Rural payment acceleration pilot; Medicare Advantage focus	Moderate
Elevance Health	ELV	ACA marketplace exposure; diversified Medicare portfolio	High
Cigna Group	CG	Strong PBM operations; commercial insurance base	Moderate
Centene	CNC	Heavy ACA marketplace reliance	High

The expiration of enhanced ACA subsidies at the end of 2025 created immediate premium pressure, with subsidized Obamacare enrollees facing average premium increases from $888 in 2025 to $1,904 in 2026 [7]. This subsidy lapse has already impacted insurer enrollment projections and could accelerate if Congress fails to extend support. However, investors have shown resilience, with shares of Centene, UnitedHealth, and Elevance rising since early December 2025 as market participants anticipate potential 2026 legislative solutions [7].

---

The administration has identified PBMs as a key source of healthcare cost inflation and announced plans to eliminate “kickbacks from pharmacy benefit managers to large brokerage middlemen” [1][2]. This reform targets the opaque rebate structures that many critics argue inflate drug prices while reducing pharmacy margins.

PBMs serve as intermediaries negotiating drug prices between pharmaceutical companies, insurers, and pharmacies. The three major PBMs—owned by UnitedHealth (OptumRx), Cigna (Express Scripts), and Elevant Health (Caremark)—process approximately 80% of US prescriptions, giving them substantial market power [8].

• UnitedHealth (UNH)
  : OptumRx represents both a competitive advantage and regulatory target; potential spin-off or restructuring may be required
• Cigna (CG)
  : Express Scripts provides vertical integration benefits but faces margin pressure from reform
• Elevance Health (ELV)
  : Caremark operations exposed to similar regulatory reform risks

Companies like Walgreens (WBA) and CVS Health (CVS) face complex dynamics:

• PBM reform could reduce reimbursement rate pressure on retail pharmacies
• However, reduced PBM revenues may lead to further network consolidation and reimbursement cuts [8]
• The long-term viability of independent pharmacies remains threatened regardless of PBM reform outcomes

---

The Trump administration has maintained several Inflation Reduction Act provisions while adjusting implementation:

• GLP-1 Coverage
  : After initial resistance, Medicare will cover GLP-1 weight-loss medications in 2026 at $245/month (beneficiary copay capped at $50), down from list prices of $1,000-$1,350 [9]
• Part D Deductibles
  : Increasing to $615 in 2026 (up from $590 in 2025) [9]
• Medicare Prescription Payment Plan
  : Automatic renewal feature implemented for 2027 [9]
• Rural Healthcare Investment
  : Largest ever federal investment in rural healthcare included in Working Families Tax Cuts legislation [2]

UnitedHealth has responded proactively to rural healthcare concerns, launching a Rural Payment Acceleration Pilot that aims to reduce Medicare Advantage payment timelines for rural hospitals from 30 days to under 15 days [6]. This initiative targets facilities in Oklahoma, Idaho, Minnesota, and Missouri, providing immediate cash-flow relief to independent rural hospitals.

---

The Great Healthcare Plan proposes expanding access to over-the-counter medications by making “more verified safe pharmaceutical drugs” available without prescriptions [2]. This policy aims to:

• Lower healthcare costs by reducing physician visit requirements
• Increase consumer choice and market competition
• Strengthen price transparency

• Retail Pharmacy Chains
  : Increased foot traffic and cross-selling opportunities
• Consumer Healthcare Companies
  : Expanded OTC market for products transitioning from prescription status

• Primary Care Physicians
  : Reduced visit volume for minor ailments
• Specialty Pharmacies
  : Decreased handling of maintenance medications

---

Subsector	Risk Level	Key Factors	Investment Thesis
Pharmaceuticals (Large Cap)	Moderate	MFN pricing, tariff exposure	Favor companies with US manufacturing commitments and diversified portfolios
Health Insurance	High	Subsidy reform, ACA uncertainty	Monitor legislative developments; prefer diversified payers with Medicare Advantage exposure
PBM/Integration Plays	High	Regulatory reform	Assess vertical integration strategies; potential restructuring scenarios
Rural Healthcare Providers	Moderate	Payment reform, rural investment	Benefit from accelerated reimbursement and federal investment
Retail Pharmacy	Moderate	OTC expansion, PBM reform	Evaluate competitive positioning and margin trajectories

Investors should track the following indicators:

1. Congressional Action Timeline
   : The legislative pathway for the Great Healthcare Plan and potential amendments
2. Voluntary Pricing Agreement Expansion
   : Additional pharmaceutical companies entering MFN deals
3. ACA Subsidy Extension
   : Congressional action on enhanced premium subsidies
4. PBM Regulatory Announcements
   : FTC and CMS guidance on kickback elimination
5. Quarterly Earnings Guidance
   : Insurer medical loss ratio trends and enrollment data

• Implementation Uncertainty
  : The plan requires Congressional approval; final provisions may differ significantly from proposals
• Legal Challenges
  : International reference pricing may face constitutional and trade agreement challenges
• Industry Lobbying
  : Pharmaceutical and insurance industries are expected to mount significant opposition
• International Retaliation
  : Drug pricing harmonization may provoke trade tensions with allied nations

---

Trump’s Great Healthcare Plan represents the most comprehensive restructuring of US healthcare policy since the Affordable Care Act. The policy framework encompasses drug pricing reform, insurance subsidy restructuring, PBM accountability measures, and expanded OTC access—all designed to lower healthcare costs while shifting market dynamics across multiple subsectors.

For investors, the policy environment creates both challenges and opportunities:

: Expect continued volatility in health insurance stocks as ACA subsidy negotiations proceed; pharmaceutical companies with voluntary pricing agreements may benefit from regulatory clarity

: PBM reform implementation will reshape the pharmacy services landscape; companies with integrated PBM operations face potential structural changes

: Manufacturing reshoring incentives and international reference pricing may permanently alter pharmaceutical company operational strategies and profitability profiles

The intersection of policy uncertainty and fundamental healthcare demand creates a complex investment environment requiring careful sector selection and active risk management.

---

[1] The White House. “Fact Sheet: President Donald J. Trump Calls on Congress to Enact The Great Healthcare Plan” (January 15, 2026). https://www.whitehouse.gov/fact-sheets/2026/01/fact-sheet-president-donald-j-trump-calls-on-congress-to-enact-the-great-healthcare-plan/

[2] The White House. “President Donald J. Trump - The Great Healthcare Plan” Official Fact Sheet (January 2026).

[3] PR Newswire. “AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans” (January 12, 2026). https://www.prnewswire.com/news-releases/abbvie-and-trump-administration-reach-agreement-to-improve-access-and-affordability-for-americans-302659062.html

[4] BDO. “2026 Life Sciences Industry Predictions” (2025). https://www.bdo.com/insights/industries/life-sciences/2026-life-sciences-predictions

[5] The Motley Fool. “Is UnitedHealth Group Stock a Buy, Sell, or Hold in 2026?” (January 14, 2026). https://www.fool.com/investing/2026/01/14/is-unitedhealth-group-stock-a-buy-sell-or-hold-in/

[6] Benzinga. “UnitedHealth Pilot Aims To Cut Rural Hospital Payment Delays In Half” (January 14, 2026). https://www.benzinga.com/markets/large-cap/26/01/49905482/unitedhealth-pilot-aims-to-cut-rural-hospital-payment-delays-in-half

[7] Reuters. “Americans facing soaring health insurance costs may get a lifeline in 2026, experts say” (December 18, 2025). https://www.reuters.com/legal/litigation/americans-facing-soaring-health-insurance-costs-may-get-lifeline-2026-experts-2025-12-18/

[8] Forbes. “Why Pharmacies Like Walgreens, Rite Aid And Independents Are Dying” (January 12, 2026). https://www.forbes.com/sites/sethjoseph/2026/01/12/why-pharmacies-like-walgreens-rite-aid-and-independents-are-dying/

[9] Kiplinger. “9 Medicare Changes to Watch in 2026” (2026). https://www.kiplinger.com/retirement/medicare/medicare-changes-coming-in-2026